Satraplatin

Identification

Name
Satraplatin
Accession Number
DB04996
Description

Satraplatin is a platinum compound that is currently under investigation as one treatment of patients with advanced prostate cancer who have failed previous chemotherapy. As an investigation drug, it has not yet received U.S. Food and Drug Administration (FDA) approval and is not available in retail pharmacies.

Type
Small Molecule
Groups
Investigational
Structure
Thumb
Weight
Average: 500.283
Monoisotopic: 499.060437065
Chemical Formula
C10H22Cl2N2O4Pt
Synonyms
  • Satraplatin
External IDs
  • BMS-182751
  • BMY-45594
  • JM-216

Pharmacology

Indication

Investigated for use/treatment in lung cancer, prostate cancer, and solid tumors.

Contraindications & Blackbox Warnings
Learn about our commercial Contraindications & Blackbox Warnings data.
Learn More
Pharmacodynamics
Not Available
Mechanism of action

This drug binds to the DNA of cancer cells, inhibiting cell division.

TargetActionsOrganism
UDNANot AvailableHumans
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half-life
Not Available
Clearance
Not Available
Adverse Effects
Learn about our commercial Adverse Effects data.
Learn More
Toxicity
Not Available
Affected organisms
  • Humans and other mammals
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
CabazitaxelThe risk or severity of adverse effects can be increased when Satraplatin is combined with Cabazitaxel.
Darbepoetin alfaThe risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Satraplatin.
DocetaxelThe risk or severity of adverse effects can be increased when Satraplatin is combined with Docetaxel.
ErythropoietinThe risk or severity of Thrombosis can be increased when Erythropoietin is combined with Satraplatin.
FosphenytoinSatraplatin can cause a decrease in the absorption of Fosphenytoin resulting in a reduced serum concentration and potentially a decrease in efficacy.
Methoxy polyethylene glycol-epoetin betaThe risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Satraplatin.
PaclitaxelThe risk or severity of adverse effects can be increased when Satraplatin is combined with Paclitaxel.
PeginesatideThe risk or severity of Thrombosis can be increased when Peginesatide is combined with Satraplatin.
PhenytoinSatraplatin can cause a decrease in the absorption of Phenytoin resulting in a reduced serum concentration and potentially a decrease in efficacy.
TopotecanThe risk or severity of adverse effects can be increased when Satraplatin is combined with Topotecan.
Additional Data Available
  • Extended Description
    Extended Description

    Extended description of the mechanism of action and particular properties of each drug interaction.

    Learn more
  • Severity
    Severity

    A severity rating for each drug interaction, from minor to major.

    Learn more
  • Evidence Level
    Evidence Level

    A rating for the strength of the evidence supporting each drug interaction.

    Learn more
  • Action
    Action

    An effect category for each drug interaction. Know how this interaction affects the subject drug.

    Learn more
Food Interactions
Not Available

Products

Categories

ATC Codes
L01XA04 — Satraplatin
Drug Categories
Chemical TaxonomyProvided by Classyfire
Description
This compound belongs to the class of organic compounds known as cyclohexylamines. These are organic compounds containing a cyclohexylamine moiety, which consist of a cyclohexane ring attached to an amine group.
Kingdom
Organic compounds
Super Class
Organic nitrogen compounds
Class
Organonitrogen compounds
Sub Class
Cyclohexylamines
Direct Parent
Cyclohexylamines
Alternative Parents
Acetate salts / Organic transition metal salts / Organic metal halides / Monocarboxylic acids and derivatives / Carboxylic acids / Organopnictogen compounds / Organic oxides / Organic chloride salts / Monoalkylamines / Hydrocarbon derivatives
show 1 more
Substituents
Acetate salt / Aliphatic homomonocyclic compound / Amine / Carbonyl group / Carboxylic acid / Carboxylic acid derivative / Carboxylic acid salt / Cyclohexylamine / Hydrocarbon derivative / Monocarboxylic acid or derivatives
show 10 more
Molecular Framework
Not Available
External Descriptors
platinum coordination entity (CHEBI:85609)

Chemical Identifiers

UNII
8D7B37T28G
CAS number
129580-63-8
InChI Key
CKNPWBAXEKSCRG-UHFFFAOYSA-J
InChI
InChI=1S/C6H13N.2C2H4O2.2ClH.H3N.Pt/c7-6-4-2-1-3-5-6;2*1-2(3)4;;;;/h6H,1-5,7H2;2*1H3,(H,3,4);2*1H;1H3;/q;;;;;;+4/p-4
IUPAC Name
platinum(4+) ion cyclohexanamine diacetate amine dichloride
SMILES
N.[Cl-].[Cl-].[Pt+4].CC([O-])=O.CC([O-])=O.NC1CCCCC1

References

General References
Not Available
PubChem Compound
123974
PubChem Substance
175426927
ChemSpider
110493
RxNav
1733681
ChEBI
85609
ChEMBL
CHEMBL3833367
Wikipedia
Satraplatin

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
3CompletedTreatmentHormone Refractory Prostate Cancer / Hormone-Refractory Prostate Cancer / Prostate Cancer1
3TerminatedTreatmentProstate Cancer1
2CompletedTreatmentLung Cancers1
2CompletedTreatmentMetastatic Breast Cancer1
2CompletedTreatmentNon-Small Cell Lung Carcinoma (NSCLC)1
2CompletedTreatmentPolymorphism, Genetic / Prostate Cancer1
2CompletedTreatmentProstate Cancer1
1CompletedTreatmentAdvanced Cancers1
1CompletedTreatmentNeoplasms, Brain / Tumors Metastatic to Brain / Tumors, Solid1
1RecruitingTreatmentProstate Cancer Patients1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
PropertyValueSource
water solubility0.4 mg/ml at pH 1-7.5Not Available
Predicted Properties
PropertyValueSource
logP1.17ChemAxon
pKa (Strongest Basic)10.45ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count1ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area26.02 Å2ChemAxon
Rotatable Bond Count0ChemAxon
Refractivity30.93 m3·mol-1ChemAxon
Polarizability12.44 Å3ChemAxon
Number of Rings1ChemAxon
Bioavailability1ChemAxon
Rule of FiveNoChemAxon
Ghose FilterNoChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET Features
PropertyValueProbability
Human Intestinal Absorption+0.6502
Blood Brain Barrier+0.7841
Caco-2 permeable-0.6468
P-glycoprotein substrateNon-substrate0.6858
P-glycoprotein inhibitor INon-inhibitor0.9881
P-glycoprotein inhibitor IINon-inhibitor0.9863
Renal organic cation transporterNon-inhibitor0.9154
CYP450 2C9 substrateNon-substrate0.8261
CYP450 2D6 substrateNon-substrate0.8462
CYP450 3A4 substrateNon-substrate0.6351
CYP450 1A2 substrateNon-inhibitor0.8764
CYP450 2C9 inhibitorNon-inhibitor0.905
CYP450 2D6 inhibitorNon-inhibitor0.9427
CYP450 2C19 inhibitorNon-inhibitor0.866
CYP450 3A4 inhibitorNon-inhibitor0.8794
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.9813
Ames testNon AMES toxic0.6304
CarcinogenicityNon-carcinogens0.811
BiodegradationReady biodegradable0.6692
Rat acute toxicity2.4085 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9732
hERG inhibition (predictor II)Non-inhibitor0.9639
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
Not Available

Targets

Kind
Nucleotide
Organism
Humans
Pharmacological action
Unknown
DNA is the molecule of heredity, as it is responsible for the genetic propagation of most inherited traits. It is a polynucleic acid that carries genetic information on cell growth, division, and function. DNA consists of two long strands of nucleotides twisted into a double helix and held together by hydrogen bonds. The sequence of nucleotides determines hereditary characteristics. Each strand serves as the template for subsequent DNA replication and as a template for mRNA production, leading to protein synthesis via ribosomes.

Drug created on October 21, 2007 16:23 / Updated on June 12, 2020 10:52

Logo pink
Are you a
new drug developer?
Contact us to learn more about our customized products and solutions.
Logo pink
Stay in the know!
As part of our commitment to providing the most up-to-date drug information, we will be releasing #DrugBankUpdates with our newly added curated drug pages.
#DrugBankUpdates